Zacks Research Comments on Globus Medical, Inc.’s Q1 2025 Earnings (NYSE:GMED)

Globus Medical, Inc. (NYSE:GMED) – Analysts at Zacks Research lifted their Q1 2025 earnings estimates for shares of Globus Medical in a note issued to investors on Monday, October 7th. Zacks Research analyst R. Department now anticipates that the medical device company will post earnings per share of $0.77 for the quarter, up from their previous forecast of $0.76. The consensus estimate for Globus Medical’s current full-year earnings is $2.84 per share. Zacks Research also issued estimates for Globus Medical’s Q2 2025 earnings at $0.81 EPS, Q4 2025 earnings at $0.82 EPS, FY2025 earnings at $3.21 EPS, Q1 2026 earnings at $0.84 EPS and FY2026 earnings at $3.78 EPS.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Tuesday, August 6th. The medical device company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.07. Globus Medical had a return on equity of 8.70% and a net margin of 1.82%. The business had revenue of $629.69 million during the quarter, compared to the consensus estimate of $615.33 million. During the same quarter last year, the firm posted $0.63 EPS. The company’s quarterly revenue was up 115.9% on a year-over-year basis.

A number of other brokerages have also commented on GMED. Barclays lifted their price target on Globus Medical from $85.00 to $93.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. Royal Bank of Canada lifted their price target on Globus Medical from $78.00 to $80.00 and gave the company an “outperform” rating in a research note on Tuesday. Morgan Stanley lifted their price target on Globus Medical from $67.00 to $71.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Globus Medical in a research note on Wednesday, August 7th. Finally, BTIG Research lifted their price objective on Globus Medical from $75.00 to $77.00 and gave the stock a “buy” rating in a research note on Wednesday, August 28th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Globus Medical currently has a consensus rating of “Moderate Buy” and a consensus price target of $77.40.

Globus Medical Stock Performance

Shares of NYSE GMED opened at $69.80 on Wednesday. Globus Medical has a 52 week low of $43.38 and a 52 week high of $74.21. The stock has a market capitalization of $9.45 billion, a P/E ratio of 108.83, a PEG ratio of 1.97 and a beta of 1.17. The stock’s fifty day moving average is $70.43 and its 200 day moving average is $65.11.

Insider Activity at Globus Medical

In other Globus Medical news, Director Ann D. Rhoads sold 15,000 shares of Globus Medical stock in a transaction on Friday, September 13th. The stock was sold at an average price of $70.36, for a total value of $1,055,400.00. Following the completion of the sale, the director now owns 42,884 shares of the company’s stock, valued at approximately $3,017,318.24. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 18.54% of the stock is owned by corporate insiders.

Institutional Trading of Globus Medical

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Select Equity Group L.P. purchased a new stake in Globus Medical during the second quarter valued at approximately $91,711,000. Millennium Management LLC raised its position in Globus Medical by 1,171.5% during the second quarter. Millennium Management LLC now owns 1,363,834 shares of the medical device company’s stock valued at $93,409,000 after purchasing an additional 1,256,570 shares during the period. Magnetar Financial LLC raised its position in Globus Medical by 198.6% during the first quarter. Magnetar Financial LLC now owns 1,689,287 shares of the medical device company’s stock valued at $90,613,000 after purchasing an additional 1,123,540 shares during the period. Motley Fool Asset Management LLC raised its position in Globus Medical by 1,263.7% during the first quarter. Motley Fool Asset Management LLC now owns 848,164 shares of the medical device company’s stock valued at $45,496,000 after purchasing an additional 785,970 shares during the period. Finally, Burgundy Asset Management Ltd. raised its position in Globus Medical by 46.1% during the first quarter. Burgundy Asset Management Ltd. now owns 2,479,837 shares of the medical device company’s stock valued at $133,018,000 after purchasing an additional 782,285 shares during the period. Hedge funds and other institutional investors own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.